vs
Ellington Financial Inc.（EFC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Ellington Financial Inc.的1.6倍（$127.1M vs $78.2M），再鼎医药同比增速更快（17.1% vs 8.7%），过去两年再鼎医药的营收复合增速更高（20.8% vs 1.8%）
埃林顿金融是一家美国对冲基金机构，专注于结构化产品及其他信贷工具领域的投资管理。截至2019年6月，公司公开披露的管理资产规模达85亿美元，在另类投资和信用资管领域拥有成熟的运营经验。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
EFC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.6倍
$78.2M
营收增速更快
ZLAB
高出8.4%
8.7%
两年增速更快
ZLAB
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $78.2M | $127.1M |
| 净利润 | $22.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 7.4% | -54.6% |
| 净利率 | 28.9% | — |
| 营收同比 | 8.7% | 17.1% |
| 净利润同比 | -26.2% | — |
| 每股收益（稀释后） | $0.10 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EFCZLAB
| Q4 25 | $78.2M | $127.1M | ||
| Q3 25 | $82.8M | $115.4M | ||
| Q2 25 | $92.5M | $109.1M | ||
| Q1 25 | $82.9M | $105.7M | ||
| Q4 24 | $72.0M | $108.5M | ||
| Q3 24 | $67.0M | $101.8M | ||
| Q2 24 | $91.2M | $100.1M | ||
| Q1 24 | $75.5M | $87.1M |
净利润EFCZLAB
| Q4 25 | $22.6M | — | ||
| Q3 25 | $29.5M | $-36.0M | ||
| Q2 25 | $42.9M | $-40.7M | ||
| Q1 25 | $31.6M | $-48.4M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $16.2M | $-41.7M | ||
| Q2 24 | $52.3M | $-80.3M | ||
| Q1 24 | $26.9M | $-53.5M |
毛利率EFCZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率EFCZLAB
| Q4 25 | 7.4% | -54.6% | ||
| Q3 25 | 31.1% | -42.3% | ||
| Q2 25 | 38.3% | -50.3% | ||
| Q1 25 | 37.3% | -53.3% | ||
| Q4 24 | 28.0% | -62.6% | ||
| Q3 24 | 24.0% | -66.6% | ||
| Q2 24 | 52.8% | -76.0% | ||
| Q1 24 | 42.2% | -80.7% |
净利率EFCZLAB
| Q4 25 | 28.9% | — | ||
| Q3 25 | 35.7% | -31.2% | ||
| Q2 25 | 46.4% | -37.3% | ||
| Q1 25 | 38.2% | -45.8% | ||
| Q4 24 | 42.6% | — | ||
| Q3 24 | 24.1% | -40.9% | ||
| Q2 24 | 57.4% | -80.2% | ||
| Q1 24 | 35.6% | -61.4% |
每股收益（稀释后）EFCZLAB
| Q4 25 | $0.10 | $-0.05 | ||
| Q3 25 | $0.29 | $-0.03 | ||
| Q2 25 | $0.45 | $-0.04 | ||
| Q1 25 | $0.35 | $-0.04 | ||
| Q4 24 | $0.23 | $-0.09 | ||
| Q3 24 | $0.19 | $-0.04 | ||
| Q2 24 | $0.62 | $-0.08 | ||
| Q1 24 | $0.32 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.9M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $715.5M |
| 总资产 | $19.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EFCZLAB
| Q4 25 | $201.9M | $689.6M | ||
| Q3 25 | $184.8M | $717.2M | ||
| Q2 25 | $211.0M | $732.2M | ||
| Q1 25 | $203.3M | $757.3M | ||
| Q4 24 | $192.4M | $779.7M | ||
| Q3 24 | $217.7M | $616.1M | ||
| Q2 24 | $198.5M | $630.0M | ||
| Q1 24 | $187.5M | $650.8M |
股东权益EFCZLAB
| Q4 25 | $1.8B | $715.5M | ||
| Q3 25 | $1.8B | $759.9M | ||
| Q2 25 | $1.7B | $791.7M | ||
| Q1 25 | $1.6B | $810.8M | ||
| Q4 24 | $1.6B | $840.9M | ||
| Q3 24 | $1.6B | $667.7M | ||
| Q2 24 | $1.6B | $704.2M | ||
| Q1 24 | $1.5B | $762.2M |
总资产EFCZLAB
| Q4 25 | $19.4B | $1.2B | ||
| Q3 25 | $17.8B | $1.2B | ||
| Q2 25 | $17.1B | $1.2B | ||
| Q1 25 | $16.6B | $1.2B | ||
| Q4 24 | $16.3B | $1.2B | ||
| Q3 24 | $16.0B | $985.3M | ||
| Q2 24 | $15.1B | $987.4M | ||
| Q1 24 | $15.1B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-925.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | -40.92× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流EFCZLAB
| Q4 25 | $-925.5M | $-26.0M | ||
| Q3 25 | $-290.4M | $-32.0M | ||
| Q2 25 | $-210.5M | $-31.0M | ||
| Q1 25 | $-126.4M | $-61.7M | ||
| Q4 24 | $-430.5M | $-55.8M | ||
| Q3 24 | $-141.7M | $-26.8M | ||
| Q2 24 | $-88.6M | $-42.2M | ||
| Q1 24 | $-59.5M | $-90.1M |
自由现金流EFCZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率EFCZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度EFCZLAB
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.0% | 1.1% |
现金转化率EFCZLAB
| Q4 25 | -40.92× | — | ||
| Q3 25 | -9.84× | — | ||
| Q2 25 | -4.90× | — | ||
| Q1 25 | -3.99× | — | ||
| Q4 24 | -14.04× | — | ||
| Q3 24 | -8.76× | — | ||
| Q2 24 | -1.69× | — | ||
| Q1 24 | -2.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EFC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
